GOFURTGO

Phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5-FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Share

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Aim

The GOFURTGO Clinical Trial aims to establish the effectiveness of new and complicated radiation tech- niques combined with new chemotherapy combinations in the treatment of patients who have localised but inoperable pancreatic cancer. People on this trial were offered initial chemotherapy, followed by a combination of radiotherapy and chemotherapy, and then consolidation chemotherapy. It is called a sandwiched regime as the radiation/chemotherapy regime is sandwiched between the initial and consolidation chemotherapy treatment.

Summary

Early detection of pancreatic cancer is difficult. People usually are not aware that they are sick. In many cases, even when the cancer is confined to the pancreas area, it is not possible to operate safely to remove the tumour. An alternative approach is to use modern chemotherapy and radiotherapy treatments. The aim of this treatment is to maximise how long the disease can be controlled, whilst maintaining a good quality of life.

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Publication Reference

Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter, IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebski VJ; on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer 2012; 106(1): 61–69.

Conference Presentation Reference

  1. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed-dose-rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Asian Oncology Summit; 9–11 Apr 2010; Nusa Dua, Bali.
  2. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4616.

Aim

The GOFURTGO Clinical Trial aims to establish the effectiveness of new and complicated radiation tech- niques combined with new chemotherapy combinations in the treatment of patients who have localised but inoperable pancreatic cancer. People on this trial were offered initial chemotherapy, followed by a combination of radiotherapy and chemotherapy, and then consolidation chemotherapy. It is called a sandwiched regime as the radiation/chemotherapy regime is sandwiched between the initial and consolidation chemotherapy treatment.

Summary

Early detection of pancreatic cancer is difficult. People usually are not aware that they are sick. In many cases, even when the cancer is confined to the pancreas area, it is not possible to operate safely to remove the tumour. An alternative approach is to use modern chemotherapy and radiotherapy treatments. The aim of this treatment is to maximise how long the disease can be controlled, whilst maintaining a good quality of life.

Principal Investigator

Conjoint Professor David Goldstein, Medical Oncologist, Prince of Wales Hospital, NSW

Clinical Associate Professor Nigel Spry, Radiation Oncologist, Sir Charles Gairdner Hospital, WA

Funding

Sanofi-Aventis Group Pty Limited (Australia),
NHMRC Clinical Trials Centre (Australia